Eli Lilly Signs Up to $2.25 Billion AI Gene Editing Deal

Eli Lilly (NYSE: LLY) announced an exclusive licensing agreement with Profluent, an AI gene editing company, with a total potential value of up to $2.25 billion. The deal grants Eli Lilly exclusive rights to develop and commercialize medicines based on Profluent's technologies, with milestone payments tied to development and commercial success.

Deal Details

• Total Value: Up to $2.25 billion.
• Payments: Includes an undisclosed upfront payment and milestone payments tied to drug success.
• Rights: Exclusive license for Eli Lilly to develop and commercialize Profluent-based medicines.
• Target Company: Profluent, specializing in AI-powered gene editing.

Rationale

The deal aims to bolster Eli Lilly's capabilities in gene editing, a promising field for treating genetic and chronic diseases. It aligns with the company's strategy to invest in cutting-edge technologies like AI to accelerate drug development.

Regulatory Challenges

Details on required regulatory approvals have not been disclosed. The deal is expected to be reviewed by regulatory bodies such as the U.S. Federal Trade Commission (FTC).

Impact on Stock

No immediate stock reaction for Eli Lilly (LLY) was reported. The deal underscores the company's commitment to biotech innovation, potentially boosting long-term investor confidence.